Geriatrics
Feature
Federal budget grants $1.8 billion to Alzheimer’s and dementia research
The largest-ever appropriation includes a $414 million boost and may be followed by $597 million more next year.
Feature
‘Aggressive’ new advance directive would let dementia patients refuse food
Critics say it’s a disturbing effort to allow withdrawal of basic sustenance from the most vulnerable in society.
Daily News Podcast
MDedge Daily News: Is kratom the answer to the opioid crisis?
And specialists have adverse reactions to drug price proposals.
Feature
Early diagnosis of Alzheimer’s could save U.S. trillions over time
Diagnosing 88% of Alzheimer’s patients in the mild cognitive impairment stage would save $7 trillion over U.S. citizens’ lifetime.
Daily News Podcast
MDedge Daily News: Why the barber’s chair can help hypertension
And how excessive daytime sleepiness could lead to dementia.
From the Journals
Excessive daytime sleepiness linked to increase in Alzheimer’s biomarker
Findings come from the first study to take a longitudinal look at excessive daytime sleepiness and beta-amyloid accumulation.
News
Consent and DNR orders
Where have the courts set the lines over the issue of consent surrounding decisions to withhold CPR?
News
No improvement in sight for Alzheimer’s drug development
If Afghanistan is the graveyard of empires, then Alzheimer’s disease is the graveyard of research dollars.
Conference Coverage
APOE4 may drive tau deposition in Alzheimer’s
The finding could offer an explanation for differences in memory loss in Alzheimer’s disease.
From the Journals
Full report confirms solanezumab’s failure to rescue cognition in mild Alzheimer’s
A full report in the New England Journal of Medicine details the latest ntiamyloid failure.
From the Journals
Idalopirdine falls short in three phase 3 Alzheimer’s trials
Simultaneously, Axovant Life Sciences pulls plug on intepirdine, another 5-HT6 receptor drug, after failures in both AD and Lewy body dementia.